Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
about
Birt-Hogg-Dube syndrome: clinicopathological features of the lungSerum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseasesReal-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complexPrevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumorsLymphangioleiomyomatosis and TSC2-/- cellsClinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis.Current views on the function of the lymphatic vasculature in health and diseaseAdolescent form of sporadic lymphangioleiomyomatosis (S-LAM).Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients.Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis.Sporadic lymphangioleiomyomatosis with bloody sputum as an initial symptom: A case report and review of the literatureRapamycin decreases airway remodeling and hyperreactivity in a transgenic model of noninflammatory lung disease.Lymphangioleiomyomatosis: what do we know and what are we looking for?Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.TSC2 modulates cell adhesion and migration via integrin-α1β1Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.Lymphangioleiomyomatosis: current and future.Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis.Cystic lung disease.Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges.Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge.Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis.Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
P2860
Q24606257-6174F997-FAF1-49B7-8EBE-CDEDF31E989BQ24608283-F4C7D65B-D4A8-4BDF-BCFC-680E80A0AFC0Q27301399-F16E11CF-871A-4CE2-B4D1-991C68ECAFC7Q30540707-D0A38B1A-2280-468A-A13E-9228AD71E4C3Q33658836-7F96640B-1F15-4CBD-8E8D-6E50007FE121Q33711691-26A2ECF6-F2E5-44E1-8788-84AD8B41162CQ33904951-1BC9FD29-206A-41F1-A0E2-128878CD7B34Q33905175-0A252F1F-0F4C-4BB6-A5CF-E63D73F051B7Q34164880-A9E34E7E-481B-4B0F-8F45-4D390E8AB461Q34429336-3F8371F8-B31B-41D2-B314-189309514499Q34598409-43B8FDB0-4959-411C-9613-E5FDB4194988Q34731132-4A353F1E-CD10-427A-B354-ED2AAEC1E0A0Q35074335-3F6AA4A0-03F6-4E47-9A80-E4D6B045F66CQ35381119-0B418157-3A37-4D5C-8042-8DBC22A57836Q35531599-5C824489-4B63-46AA-A327-ABF4A5F11E39Q35758056-82BB9559-0D12-4B39-B440-88121D02D823Q35789958-9FBB3993-5F89-4F96-9916-1711247D574CQ36067383-C541797F-FB2E-4F06-A015-E61E1C2E45B0Q36232850-E9903B36-F4CE-4F2E-9238-112362A6EC1DQ36312486-76B26CB5-91D0-41A9-B92A-FE64A43BC120Q36402424-54C1394D-67F8-4F65-8888-C89F67D121D2Q36542254-C35AF6B4-CCCC-49C3-93F3-C7689AA2EAB3Q36636671-BA196D0C-5E51-42B9-B416-350CD25A55A5Q37038088-A610941A-78FE-4501-8BFB-8A112F1D5961Q37245454-7631BFAD-5039-4172-BCC5-A1D9E0944D04Q38111303-F389112E-09FB-454C-8660-82232B68C28CQ38463698-408254BD-BD56-4319-AF5F-2FD0A21603E4Q42595723-6E95F6C9-55F2-4ABA-867E-5DCBAE0C5B0CQ43182213-3091D1B8-B38C-492B-B6BF-5A6DE0265F2EQ47656318-FC829C2E-514D-4636-A9C0-059577B59C19Q47662133-4FC2B4CA-97E3-4843-8424-A56FF9274222Q51779283-A0DA4D5C-F2FB-4D90-835B-DEDC04FC3FC7
P2860
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
@ast
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
@en
type
label
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
@ast
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
@en
prefLabel
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
@ast
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
@en
P2860
P50
P356
P1476
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans
@en
P2093
David J Kwiatkowski
P2860
P304
P356
10.1165/RCMB.2006-0372TR
P577
2006-11-10T00:00:00Z